Project Grant R56DK140492
Award Date
9/2/24
Completion Date
8/31/25
Dollars Obligated
$595K
Federal Grant Program
93.847
Assistance Type
Project Grant
Place of Performance
Sacramento, CA 95817, USA
Similar Awards
This Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), provides $938,470 to the University of Massachusetts Medical School to investigate a novel adipokine that may resolve non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) in mouse models. The award period runs from September 1, 2024 to June 30, 2028. The research aims...
This Project Grant award from the National Cancer Institute (CFDA Program 93.396 - Cancer Biology Research) totaling $2,397,277 will support research at the Sanford Burnham Prebys Medical Discovery Institute to investigate the role of metabolic stress and hypernutrition in the progression from non-alcoholic steatohepatitis (NASH) to hepatocellular carcinoma (HCC). The research will focus on understanding how interactions between cellular signaling pathways (NRF2, ATF6) and mitochondrial...
This Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), provides $516,648 to The Leland Stanford Junior University to conduct research on understanding the mechanisms by which microbially derived metabolites regulate host gut inflammation. The award period runs from August 28, 2024 to February 28, 2027. The research aims to determine the regulatory...
This Project Grant award of $790,359.00 from the National Institute of Diabetes and Digestive and Kidney Diseases (CFDA 93.847 Diabetes, Digestive, and Kidney Diseases Extramural Research) supports research to develop a targeted probiotic yeast therapeutic for treating inflammatory bowel diseases (IBD) such as Crohn's disease and ulcerative colitis. The award will fund the design, characterization, and optimization of a bioengineered Saccharomyces boulardii yeast that can secrete nanobody...
This Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) provides $546,625.00 to the University of Pittsburgh to develop a novel nanocarrier-based immunochemotherapy for the treatment of metastatic colorectal cancer (mCRC). The key products and services to be delivered include: Developing and characterizing a nanoparticle carrier capable of co-delivering small interfering RNA targeting the IRHOM1 protein and a prodrug conjugate of...
This Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), provides $599,541.00 to the University of Colorado-Denver to study the role of antigen-specific T cell responses in non-alcoholic steatohepatitis (NASH). The overarching goal is to define the timing of T cell clonal expansion, the antigens recognized by clonally expanded T cells, the antigen...
This federal Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), is dedicated to the development and optimization of non-peptide ligands designed to activate insulin receptors. The $772,383 research project aims to transform approaches to glycemic control in the management of diabetes by uncovering a new generation of receptor modulators that could...
The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) awarded Biotherapeutics, Inc. a $359,625 Project Grant under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847). The grant supports the development of next-generation, once-daily oral therapeutic candidates for the treatment of pre-diabetes and type 2 diabetes. Key research objectives include evaluating the therapeutic efficacy of the lead drug candidate on lipid metabolism, insulin...
The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) awarded a $664,769 Project Grant under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to Oregon Health & Science University (OHSU). The grant, awarded on July 1, 2025, supports research to overcome barriers to therapeutic hepatocyte transplantation. Specifically, the project aims to genetically enhance donor hepatocytes to make them immune stealthy and expandable, enabling...
This $391,250 Project Grant awarded by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) will support research on extracellular vesicle-dependent RNA signaling in metabolism. The project aims to identify key proteins involved in the delivery of adipose microRNAs into liver cells via extracellular vesicles, and to determine if this RNA delivery mechanism is necessary for...